Innoviva Stock (NASDAQ:INVA)
Previous Close
$19.41
52W Range
$12.22 - $19.85
50D Avg
$17.98
200D Avg
$16.09
Market Cap
$1.19B
Avg Vol (3M)
$515.19K
Beta
0.57
Div Yield
-
INVA Company Profile
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Performance
Peer Comparison
Ticker | Company |
---|---|
INCY | Incyte Corporation |
XFOR | X4 Pharmaceuticals, Inc. |
DNLI | Denali Therapeutics Inc. |
APLS | Apellis Pharmaceuticals, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
PDSB | PDS Biotechnology Corporation |
HOOK | HOOKIPA Pharma Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
HRMY | Harmony Biosciences Holdings, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
FOLD | Amicus Therapeutics, Inc. |
LIFE | aTyr Pharma, Inc. |
ELEV | Elevation Oncology, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |
ARGX | argenx SE |